Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria

AUTOR(ES)

Fivelman, Quinton L

FONTE

BioMed Central

RESUMO

We report the first in vitro and genetic confirmation of Malarone® (GlaxoSmithKline; atovaquone and proguanil hydrochloride) resistance in Plasmodium falciparum acquired in Africa. On presenting with malaria two weeks after returning from a 4-week visit to Lagos, Nigeria without prophylaxis, a male patient was given a standard 3-day treatment course of Malarone®. Twenty-eight days later the parasitaemia recrudesced. Parasites were cultured from the blood and the isolate (NGATV01) was shown to be resistant to atovaquone and the antifolate pyrimethamine. The cytochrome b gene of isolate NGATV01 showed a single mutation, Tyr268Asn which has not been seen previously.

Documentos Relacionados

• Salmonellosis in Lagos, Nigeria: Incidence of Plasmodium falciparum-associated Co-infection, Patterns of Antimicrobial Resistance, and Emergence of Reduced Susceptibility to Fluoroquinolones
• Epidemic acute haemorrhagic conjunctivitis in Lagos, Nigeria.
• Patterns of delays amongst pulmonary tuberculosis patients in Lagos, Nigeria
• Extended-Spectrum β-Lactamase Enzymes in Clinical Isolates of Enterobacter Species from Lagos, Nigeria
• Prevalence of cervical chlamydial infection in antenatal clinic attenders in Lagos, Nigeria.